Tenax Therapeutics, Inc.
TENX· Nasdaq
TENXTenax Therapeutics, Inc.
Source filing unavailable
| Metric | Q2 2015 | Q2 2012 | Q2 2011 |
|---|---|---|---|
| Revenue | — | $95.16K | $27.13K |
| Net Income | -$4.75M | -$2.93M | $2.05M |
| EPS Diluted | -$0.17 | -$0.29 | -$0.09 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
